Parkinson's disease
274 results
1 - 100
Creatine for Parkinson's disease
Parkinson's disease - Amantadine in Parkinson's disease
Coenzyme Q10 ineffective in Parkinson's disease- Amantadine for dyskinesia in Parkinson's disease
- Tremor and rigidity in Parkinson's disease - Video
- Lisuride for levodopa‐induced complications in Parkinson's disease
- Non‐pharmacological therapies for dysphagia in Parkinson's disease
- Dopamine agonist therapy in early Parkinson's disease
- Occupational therapy for patients with Parkinson's disease
- Occupational therapy for patients with Parkinson's disease
- Cabergoline for levodopa‐induced complications in Parkinson's disease
- Beta‐blocker therapy for tremor in Parkinson's disease
- Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease
- Antidepressants for depression in Parkinson's disease
- Physiotherapy for patients with Parkinson's disease
- Parkinson's disease dementia and dementia with Lewy bodies
- Treadmill training for patients with Parkinson's disease
- Helicobacter pylori eradication for Parkinson's disease: Cochrane systematic review
- Cholinesterase inhibitors for Parkinson's disease dementia
- Interventions for fatigue in Parkinson's disease
- Therapies for depression in Parkinson's disease: Cochrane systematic review
- Bromocriptine versus levodopa in early Parkinson's disease
- Ropinirole versus bromocriptine for levodopa‐induced complications in Parkinson's disease
- Coenzyme Q10 for Parkinson's disease: Cochrane systematic review
- Lisuride versus bromocriptine for levodopa‐induced complications in Parkinson's disease
- Selegeline for early Parkinson's disease
- Monoamine oxidase B inhibitors for early Parkinson's disease
- Catechol‐O‐methyltransferase inhibitors for levodopa‐induced complications in Parkinson's disease
- Treadmill training for patients with Parkinson's disease
- Cabergoline versus bromocriptine for levodopa‐induced complications in Parkinson's disease
- Dopamine agonist therapy in early Parkinson's disease
- Pergolide for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
- Bromocriptine versus levodopa in early Parkinson's disease
- Treating dopamimetic psychosis in Parkinson's disease
- GLP‐1 receptor agonists for Parkinson's disease
- Cabergoline for levodopa-induced complications in Parkinson's disease
- Pramipexole for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
- Pharmacological and non‐pharmacological treatments for impulsive‐compulsive behaviors in Parkinson's disease
- Bromocriptine for levodopa‐induced motor complications in Parkinson's disease
- Physiotherapy for Parkinson's disease: a comparison of techniques
- Interventions for fatigue in Parkinson's disease
- Ropinirole for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
- Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
- Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease
- Bromocriptine/levodopa combined vs. levodopa alone for early Parkinson's disease
- Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease: Cochrane systematic review
- Speech and language therapy interventions for speech problems in Parkinson's disease
- Interventions for orthostatic hypotension in Parkinson's disease: a systematic review and network meta‐analysis
- Cholinesterase inhibitors for Parkinson's disease dementia: Cochrane systematic review
- Bromocriptine/levodopa combined versus levodopa alone for early Parkinson's disease
- Virtual reality for rehabilitation in Parkinson's disease
- Catechol‐O‐methyltransferase inhibitors versus active comparators for levodopa‐induced complications in Parkinson's disease
- Transcranial direct current stimulation (tDCS) for idiopathic Parkinson's disease
- Speech and language therapy for dysarthria in Parkinson's disease
- Speech and language therapy versus placebo or no intervention for speech problems in Parkinson's disease
- Physiotherapy versus placebo or no intervention in Parkinson's disease
- Interventions for preventing falls in Parkinson's disease
- Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
- Monoamine oxidase B inhibitors versus other dopaminergic agents in early Parkinson's disease
- Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies: Cochrane systematic review
- Comparison of speech and language therapy techniques for speech problems in Parkinson's disease: Cochrane systematic review
- Anti-hypertensive drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies and clinical trials: Cochrane systematic review
- Physical exercise for people with Parkinson’s disease: a systematic review and network meta‐analysis
- Cognitive training interventions for dementia and mild cognitive impairment in Parkinson’s disease